Search

Your search keyword '"Gibney GT"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Gibney GT" Remove constraint Author: "Gibney GT"
81 results on '"Gibney GT"'

Search Results

1. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

3. Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.

4. A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.

6. Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation.

7. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

8. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.

9. Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.

10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.

11. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

12. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.

13. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.

14. Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.

15. Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions.

16. Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.

17. PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.

18. Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.

19. The State of Melanoma: Emergent Challenges and Opportunities.

20. A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis.

21. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.

22. Linear IgA Disease of the Gingiva Following Nivolumab Therapy.

23. The current state of molecular testing in the treatment of patients with solid tumors, 2019.

24. YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.

25. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

26. Choice of first-line therapy in metastatic melanoma.

27. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E -Mutant Melanoma.

28. Clinical characterization of colitis arising from anti-PD-1 based therapy.

29. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

31. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.

32. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

33. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

34. Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.

35. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.

36. Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

37. Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes.

38. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.

39. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.

40. Advances in immunotherapy for melanoma.

41. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

42. XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.

43. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.

44. Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?

45. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.

46. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.

47. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.

48. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.

49. Beyond BRAF: where next for melanoma therapy?

50. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.

Catalog

Books, media, physical & digital resources